GlassScriptPhysician profile
Celeste Y Sorah
NPI 1790101558
$6,114.62
in general payments reported to CMS, 2019-2025
25 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,244 · 2022: $1,202 · 2023: $1,255 · 2024: $1,370 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,668.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $982.09 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $856.20 | 2021-2025 | Tagrisso, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.14 | 2021-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $470.96 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $437.61 | 2021-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $436.82 | 2021-2024 | Acthar |
| United Therapeutics Corporation | $310.69 | 2021-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $290.95 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $288.78 | 2024-2025 | Dupixent |
| Baxter Healthcare | $244.88 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $237.18 | 2022-2025 | Zerbaxa, Recarbrio |
| Mylan Specialty L.P. | $203.19 | 2021-2024 | Yupelri |
| Amgen INC. | $180.17 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $102.60 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $88.71 | 2023-2024 | Uptravi, Opsumit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $88.43 | 2021-2024 | Fetroja |
| Ani Pharmaceuticals, INC. | $78.10 | 2023-2024 | Purified Cortrophin Gel |
| Insmed, INC. | $74.60 | 2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $70.37 | 2021 | |
| Inogen, INC. | $52.39 | 2022-2024 | |
| La Jolla Pharmaceutical Company | $46.35 | 2025 | Zevtera, Giapreza |
| Janssen Pharmaceuticals, INC | $31.58 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $23.37 | 2023 | |
| Electromed, INC. | $18.56 | 2022 | |
| Advanced Respiratory, INC | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Sorah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.